KYTX
NASDAQ · Biotechnology
Kyverna Therapeutics Inc
$7.96
+0.21 (+2.71%)
Open$7.95
Previous Close$7.75
Day High$8.13
Day Low$7.76
52W High$13.67
52W Low$2.80
Volume—
Avg Volume781.3K
Market Cap471.16M
P/E Ratio—
EPS$-3.28
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+2.5% upside
Current
$7.96
$7.96
Target
$8.16
$8.16
$5.68
$8.16 avg
$10.96
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 77.52M | 81.06M | 62.85M |
| Net Income | -14,424,701 | -12,557,463 | -9,873,224 |
| Profit Margin | -18.6% | -15.5% | -15.7% |
| EBITDA | -20,391,428 | -20,108,436 | -16,996,352 |
| Free Cash Flow | -5,835,314 | -8,946,067 | -4,753,485 |
| Rev Growth | +5.4% | +22.1% | -7.0% |
| Debt/Equity | 0.25 | 0.20 | 0.25 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |